Success Holdings Group International and Freedom Energy Holdings Annouce the Sale and Purchase Of Majority Ownership Of Launch TV
Fort Wayne, Indiana (UPTICK Newswire) December 19, 2014 – Success Holdings Group International (OTC QB: SHGT) and Freedom Energy Holdings, Inc. (Pink Sheets: FDMF.PK) today announced the sale and purchase of the majority ownership of Launch TV Network Company, a Virginia corporation and previously the wholly owned subsidiary of FDMF (“Launch TV”).
Per the terms of the definitive agreement, in exchange for 500,000 restricted shares of SHGT ‘s common shares, SHGT purchased from FDMF 55% of Launch TV. The shares of SHGT will carry a 24 month lock up.
Steve Chen, Chairman of SHGT commented, “I am extremely excited to bring in our first acquisition of a USA operation. The Launch TV platform is a perfect fit for our entertainment and video distribution. SHGT is currently seeking and identifying private and public companies in Asia as acquisition and merger candidates. It is my vision to have SHGT listed on the Frankfurt Stock Exchange and AMEX in fist half of 2015. This will give SHGT the leverage to acquire more valuable companies in throughout Asia and the USA.”
Brian Kistler, CEO of FDMF stated, “When I acquired Launch TV about 8 months ago I had full intention of eventually introducing Launch TV to Mr. Chen. The timing was not right for SHGT to get involved with Launch TV in April of 2014 but now that it has a firm foothold and moving forward with its plans it is a match made in Heaven. The shares of SHGT will be held in the name of FDMF and will be distributed in a stock dividend to the shareholders of FDMF at some point (within the lockup). The date for the dividend is still to be determined but until then will remain an asset of FDMF.”
Launch TV reaches a national audience of 40+ million in Europe and America; it can be viewed live on ROKU, iPad, iPhone, Android and Smart TV devices via iPoint TV. Launch TV is planning to expend its market into Asia in 2015.
Future Business Operations
SHGT is currently seeking and identifying private and public companies in Asia as acquisition and merger candidates. SHGT is currently trading on the USA OTC markets and is now forecasting pretax earnings of $0.4~$0.5 per share. It is Mr. Chen’s vision to have SHGT listed on the Frankfurt Stock Exchange soon and AMEX in the near future. This will give SHGT leverage to acquire more valuable companies in Asia. Mr. Chen and SHGT will focus on integration of chain stores and brand names, IOT (Internet of Things), alternative energy technology, internet and logistics. Mr. Chen stated “Through the newly structured public company, we will be able to pursue more aggressively to acquire quality companies in Asia. We have plans to invest or acquire up to 30 companies within the next ten to fifteen years, and our shareholders should be able to reap the benefit of the higher growth potential in the Asia region.
FORWARD LOOKING STATEMENT-This press release contains certain “forward‐looking” statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward‐looking statements. The Company, through its management, makes forward‐looking public statements concerning it expected future operations, performance and other developments. Such forward‐looking statements are necessarily estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, the Company’s ability to develop operations, the Company’s ability to consummate and complete the acquisition, the Company’s access to future capital, the successful integration of acquired companies, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, sales and other factors that may be identified from time to time in company’s public announcements.
Urban Barns Foods Inc. (OTCQB: URBF)(“Urban Barns”), an innovative food producer dedicated to growing consistent, healthy and fresh vegetables year round using its proprietary Cubic Farming™ method, today provides its shareholders with an update on its research and development (R&D) activities at McGill University.
In its yearly update to Urban Barns the Biomass Production Laboratory research team at McGill University reported that research jointly sponsored by Urban Barns and an NSERC Cooperative Research & Development (CRD) grant is being used to design and test optimum light emitting diode (LED) light bars to maximize production and reduce energy costs in the Cubic FarmingTM system of Urban Barns. The focus of the NSERC research is optimizing light emitting diodes to assess photosynthetically active radiation efficiency (PAR curve) of horticultural plants using different wavelengths of LED at both low and high irradiance levels. To support this basic research a Cubic FarmingTM unit is operating on the Macdonald Campus of McGill University, Faculty of Agricultural and Environmental Sciences.
In addition to the research being undertaken as a part of the NSERC CRD grant, researchers are focused on expanding the range of horticultural crops being grown on the Cubic FarmingTM system to include bell peppers, tomatoes, and strawberries. Four new trough designs are being tested to support these fruiting crops. Researchers also report that new biological rooting substrates that can be easily incorporated into the Cubic FarmingTM system are being tested to replace non-biodegradable rockwool. This ongoing research has had very promising results with several different substrate materials that are all biodegradable.
Dr. Mark Lefsrud is the principal investigator and team leader with expertise on the use of LED lighting in greenhouse environments. The research team includes Dr. Valerie Gravel, Assistant Professor in Plant Science, and includes 10 research support professionals including graduates, undergraduates and research associates, with expertise split between the engineering and horticultural aspects of the project. The team is focused on performing research on methods and technologies to grow food and other plants in a more energy-efficient manner while also attempting to improve the nutritional value of the food grown.
Like, follow, discuss, and keep up to date:
About Urban Barns Foods Inc.
Urban Barns uses patent pending and proprietary equipment to produce affordable leafy vegetables in a secure and controlled indoor environment. By setting up subsidiary facilities and growing locally, Urban Barns can focus on supplying any community, irrespective of the regional climate, effectively reducing shipping times and related spoilage costs. Urban Barns has the unique ability to scale and cater to the demands of all major communities. The company’s commitment to consumers is reflected through its motto, “Purely Fresh, Naturally Tasty, and Completely Healthy”.
Except for historical information contained herein, the matters set forth above may include forward-looking statements that involve certain risks and uncertainties. Words such as “may”, “could”, “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, and similar expressions are used to identify forward-looking statements. These forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements. Urban Barns does not undertake any obligation to update any forward-looking statements and cautions investors to consider all other risks and uncertainties, including those disclosed in Urban Barns’ filings with the United States Securities and Exchange Commission.
For further information, contact:
Innovus Pharma Expands Agreement with Tramorgan Limited to Commercialize Vesele® in the United Kingdom
San Diego, Calif., December 16, 2014 – Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) www.innovuspharma.com (OTCQB:INNV) announced today it has expanded its exclusive marketing and distribution agreement with Tramorgan Limited (“Tramorgan”) ,and granted to Tramorgan additional rights to market and sell Innovus Pharma’s oral dietary supplement to promote sexual and cognitive health, Vesele® in the United Kingdom (“UK”). Under the agreement, Innovus is eligible to receive up to $13 million dollars in sales milestone payments plus fifty percent (50%) royalties based on Tramorgan’s sales of Vesele® in the UK.
The product will be available in a 120 capsule bottle and will be priced at $26.50 per bottle online and $32.00 in retail stores.
“This is an expansion of our agreement with Tramorgan and our first agreement in Europe for the distribution and sale of Vesele®. We are very pleased with our relationship with Tramorgan and the level of sales we are beginning to see from their efforts”, said Dr. Bassam Damaj, Ph.D. President & CEO of Innovus Pharma.
“We continue to expand the markets for our products as we approach our goal to make all of our products available in at least 40 countries by the end of 2015,” continued Dr. Damaj.
“Our ability to secure a distribution and sales agreement in a large European market for Vesele®, a product that we acquired recently, is a testimony to the strength and readiness of our international distribution channels and the robustness of our distribution infrastructure,” added Dr. Damaj.
Vesele® is a proprietary, novel oral dietary supplement to maximize nitric oxide’s beneficial effects on sexual function and brain health. Vesele® contains a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine®.
The beneficial effects of Vesele® on sexual and cognitive functions were confirmed in a four month US clinical survey study involving 152 patients (69 men and 83 women). Results from the clinical survey have indicated (1) improvement of erectile hardness and maintenance in men and increased sexual intercourse frequency with their partners and (2) lubrication in women, when taken separately by each. Positive effects on brain health were translated by an increase in recall of words and names.
For more information visit www.myvesele.com
Tramorgan is a UK-based company with many years of experience in assisting European and global pharmaceutical companies to expand and deliver their products to markets in Europe and other countries. Tramorgan specializes in niche products that require specialist knowledge and market expertise in obtaining sales through the UK NHS hospital market, as well as OTC and other medical channels. The Company provides advice to healthcare organizations, universities and other commercial operations, wishing to develop or spin out unique pharmaceutical product portfolios or innovations and commercialize them for competitive international markets.
For more information about Tramorgan, please contact Heather Crawford at email@example.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men’s and women’s health and vitality. The Company generates revenues from its lead products Zestra® for female arousal, and EjectDelay™ for premature ejaculation, and has a total of five marketed products in this space, including Sensum® (for sales outside the U.S. only), Zestra Glide® and Vesele® for promoting sexual and cognitive health.
Innovus Pharma’s Forward-Looking Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether Tramorgan will be able to successfully market and sell Vesele® in the United Kingdom. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.
Innovus Pharma Contact: